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Introduction
Diabetes is a significant cause of chronic kidney disease (CKD) 
and there is an increased risk of anaemia in type 2 diabetes 
(T2DM) with CKD (Thomas et al., 2005; Al-Khoury et al., 
2006; National Institute for Clinical Excellence (NICE) 2006; 
Mostafa et al., 2009). CKD and diabetes are increasing globally. 
Rates of anaemia associated with diabetes-related CKD range 
from 11% to 23% (Thomas et al., 2004; Craig, 2005; Cawood et 
al., 2006) with higher rates in females in some studies (Cawood 
et al., 2006; Li Vecchi et al., 2007). Other researchers report 
higher rates in males (Craig et al., 2005) but the reason for the 
difference between the genders is unclear. CKD occurs in both
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Abstract
Introduction: Diabetes is the major cause of chronic kidney disease (CKD) in Australia. Anaemia of CKD occurs earlier than 
in non-diabetics and is often insidious and undetected. 
Aim: A large, prospective, single-centre study was undertaken to determine the feasibility of point of care testing (POCT) 
haemoglobin (Hb) and microalbumin in people with type 2 diabetes (T2DM) attending routine outpatient clinic appointments 
(OPC).
Method: Clinic nurses measured Hb and microalbumin using the HemoCue Haemoglobin Capillary Analyser and the 
HemoCue Urine Albumin Analyser (Medipac Scientific), respectively when they tested blood glucose, weight and blood 
pressure. The nurses were trained to use the analysers before the study commenced. Standard demographic data, duration of 
diabetes, treatment mode, and presence of complications, comorbidities, and HbA
1c
 were ascertained from patients’ medical 
records.
Results: Five hundred and fifty-four (80%) patients were screened. The nurses were able to perform the tests competently 
but testing, especially microalbumin, was time-consuming. Patients’ mean age was 62 years (11 SD): 230 females, mean blood 
glucose (BG) 10 (3.9 SD) mmol/L, mean haemoglobin 127.2 (16.3 SD) g/L; mean microalbumin 47.8 (58.7 SD) mg/L: 
324 were males, mean BG 10.2 (3.9 SD) mmol/L, mean Hb 138.6 (18.8 SD) gm/L, and mean microalbumin 67.9 (73.9 
SD) mg/L. 27% of males and 22% of females were anaemic. Of those with anaemia, 27% of females and 29% of males had 
microalbuminuria.
Conclusions: POCT is feasible in routine outpatient clinics but is time-consuming. One in four T2DM attending OPC were 
anaemic. POCT Hb testing in OPC is feasible and could identify T2DM who need full haematological assessment.
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type 1 (T1DM) (Thomas et al., 2004) and T2DM diabetes and 
the pathogenesis is similar in both types (Stanton, 2000).
Erythropoietin (EPO) concentration is predictive of the rate of 
progression of CKD; however, epidemiological studies do not 
show lower haemoglobin (Hb) in people with diabetes (PWD) 
without renal disease (Dikow et al., 2002). However, PWD with 
anaemia have more severe CKD than those without anaemia, 
and the anaemia occurs at an earlier stage than in non-diabetics 
with similar disease severity (Bosman et al., 2002; Li Veccchi 
et al., 2007; Mostafa et al., 2009). In fact, anaemia is common 
in the early stages of diabetes-related kidney disease and Hb is 
lower by an average of 10 g/dL at every level of renal function 
in PWD compared to non-diabetics (Al-Khoury et al., 2006).
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CKD is primarily microvascular in origin. It frequently occurs 
with other diabetic vasculopathies and is associated with the 
duration of diabetes. In addition, pre-existing retinopathy is 
present in 90% of people with CKD, especially those with 
T1DM (Thomas et al., 2004). Microalbuminuria is an early 
clinical manifestation of CKD, and is also a predictor of vascular 
risk, and an early marker of early death from cardiac disease. If 
treatment is not instituted, 20%–40% PWD develop overt CKD. 
The onset and progression of CKD correlates with glycaemic 
control. Normalising blood glucose slows the onset and 
progression of CKD (Diabetes Control and Complication Trial 
(DCCT) 1993; Marks & Raskin, 1998) in addition to improving 
cardiovascular status by controlling blood pressure and smoking 
cessation (Locatelli et al., 2004).
Anaemia is defined as Hb < 13 g/dL in males and < 12 g/
dL in females (World Health Organization (WHO) 2008). 
Significantly, anaemia is often symptomless, apart from lethargy, 
which can be attributed to hyperglycaemia, depression, 
increasing age and other causes. The symptoms vary with the 
speed of onset and the Hb level: the lower the Hb the more 
severe the symptoms. Diabetes-related anaemia is usually 
normocytic and normochromic and may be due to several 
interrelated causal mechanisms.
PWD are twice as likely to be anaemic than non-diabetics with 
renal disease from other causes: at least one in five DM attending 
outpatient clinics is anaemic (Thomas et al., 2006). Li Vecchi et 
al. (2007) found higher anaemia rates in PWD with stages four 
and five CKD (16%) than non-diabetics, and females had lower 
Hb levels than males. Likewise, in the KEEPS study (Obrador 
et al., 2010) 27% of 5380 participants had diabetes: 11.6% were 
anaemic compared to 6.35% of non-diabetics. In addition, 
anaemia is prevalent in residents in aged care facilities for various 
reasons including nutritional deficiencies, hypertension and 
multiple comorbidities, diabetes and renal and vascular disease 
(Resnick, 2009).
Anaemia affects physical performance, possibly due to reduced 
red cell oxygen carrying capacity leading to tissue hypoxia, 
which puts the individual at risk of reduced muscle strength 
and falls. Mood and quality of life are also affected. It is possible 
that early detection and instituting preventative management 
strategies such as optimising iron levels, excluding and correcting 
reasons for blood loss and education could improve patient 
outcomes. Improved quality of life, increased exercise capacity 
and reduced ventricular hypertrophy have been demonstrated 
in patients with cardiovascular disease when anaemia is treated 
(MacDougall, 2000). Other benefits include improved cognitive 
function (Lawrence et al. 1997) and wellbeing, which could be 
partly due to attending to underlying pathologic processes early 
and throughout the person’s life (van Ypersele de Strihou, 1999).
Recognising renal anaemia early could improve all these issues. 
However, anaemia screening is not routinely performed as part 
of diabetes complication screening, although such screening may 
occur during acute illnesses such as myocardial infarction and 
infection (Al-Khoury et al., 2006). Point of care testing (POCT) 
makes routine screening more achievable and is an alternative to 
laboratory investigations for a number of health parameters such 
as HbA
1c
, microalbuminuria, International Normalised Ratio 
(INR) and anaemia. POCT refers to analytical tests performed 
outside the laboratory (Kost, 2002). POCT is equivalent to 
laboratory testing for HbA
1c
, urine albumin, albumin-creatine 
ratio, total cholesterol and triglycerides (Bubner et al., 2009).
POCT enables clinicians to have access to key information 
at the time of the consultation, which helps them detect risk 
parameters early. It is particularly useful for non- and irregular 
health care attendees, and can be used to involve patients in their 
care. Thus, POCT can facilitate proactive disease monitoring, 
clinical decision-making, and timeliness of interventions, which 
can improve outcomes (Bubner et al., 2009). However, routine 
POCT Hb testing might not be feasible in diabetic outpatient 
clinics. Currently, clinic nurses routinely weigh patients and 
measure their blood glucose and blood pressure and record the 
results in the medical record before the diabetologist and/or 
diabetes educator and dietitian assess the patient. The impact of 
the extra screening on clinic nurses’ workload is not clear.
Aim of the study
The aim of the study was to explore the feasibility of POCT 
Hb and microalbumin in people with T2DM attending routine 
outpatient clinic appointments (OPC).
Method
Clinic nurse role and training
The three regular clinic nurses participated in the prospective, 
single-centre study. The nurses were all female and had worked 
in the diabetes clinic for at least four years. Their regular role 
includes weighing each patient, testing capillary blood glucose, 
testing blood ketones if the individual is hyperglycaemic 
(especially T1DM) and measuring the blood pressure before 
the clinicians assess the patient. In order to address the study 
aim, the clinic nurses tested Hb and microalbumin in diabetic 
clinic attendees using the HemoCue Haemoglobin Capillary 
Analyser and the HemoCue Urine Albumin Analyser (Medipac 
Scientific), respectively, over three months (April to June 2009).
The analysers are photometric devices with established 
sensitivity and specificity in a range of populations and 
conditions (Sari et al., 2001; Nuefield et al., 2002). The analysers 
were subject to routine quality assurance testing by the hospital 
laboratory staff during the current study to ensure they read 
within the recommended reference range. The test protocol was 
based on the Australian Government Department of Health and 
Aging (DOHA) (2004) POCT standards. However, sensitivity 
and specificity testing was considered unnecessary.
The three nurses were trained to obtain blood and urine samples 
and to measure Hb and urine using the HemoCue analysers, 
prior to commencing the study. Training consisted of the 
HemoCue representative demonstrating the correct technique 
for each test; each nurse then independently performed Hb 
and microalbumin tests until they accurately performed six 
consecutive Hb and six consecutive microalbumin tests correctly. 
The HemoCue representative attended the clinic for the first 
week of the study to provide advice and support, if required.
The nurses collected capillary blood for Hb tests at the same 
time they collected blood for glucose testing, usually from the 
same finger-prick site. Patients were provided with a labelled 
sterile urine container and asked to collect a urine sample, 
which they gave to the clinic nurse for microalbumin analysis. 
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The results of all tests were recorded in the study database and 
the patient’s medical record and were available to the clinicians 
during the consultation.
At the end of the three months’ data collection period, all three 
clinic nurses participated in brief, individual, open interviews to 
explore their perceptions of the usability of the devices and the 
feasibility of continuing routine Hb and microalbumin testing 
in the clinic, in addition to routine blood glucose, weight and 
blood pressure monitoring. One researcher, experienced in 
interview techniques, conducted the interviews. The interviews 
were audio-taped and transcribed verbatim before being de-
identified and analysed. Each interview took approximately 15 
minutes (longer time was not available in the busy clinic setting).
Patient sampling population and sample
The patient sample consisted of T2DM attending their routine 
diabetic outpatient clinic appointments during the study period. 
The majority is over 40 years and has a range of durations of 
diabetes and multiple diabetes complications (vascular disease, 
retinopathy, nephropathy and neuropathy). A range of cultures 
attends, predominantly Greek, Italian, Vietnamese, Turkish and 
Australian. Diabetes is treated according to individual needs with 
diet and exercise, oral hypoglycaemic agents (OHA), insulin or a 
combination of these treatments. 
Between 50 and 60 patients attend each clinic and clinics are 
held weekly. A convenience sample was recruited. The clinic 
nurses invited patients to participate when they presented for 
routine pre clinic screening. If necessary, an interpreter explained 
the study to the patient. Standard demographic and biochemical 
data were collected from the patient’s medical record and 
included: age, gender, duration of diabetes, complications 
present, blood pressure, HBA
1c
, lipids, microalbuminuria, 
proteinuria and GFR by creatine clearance.
Data analysis
The nurse interview data were analysed using the framework 
method (Ritchie & Spencer, 1994). This method consists of 
a five-step process that involves reading and rereading each 
transcript line-by-line to become familiar with the data and to 
identify frequently occurring words and possible themes. The 
emerging themes were then indexed and grouped into key 
themes. Two researchers independently analysed the transcripts 
by hand, identified themes and then met to discuss their findings 
and reach consensus.
Patient data were entered into a Statistical Package for the 
Social Sciences (SPPS) 15.0 software (SPSS Inc., Chicago, IL) 
for analysis. Descriptive statistics including percentages range, 
mean and standard deviation were calculated. Relationships 
between demographic and biochemical variables were assessed 
using Pearsons correlations, t-tests, and Chi square tests. 
The significance level was set at p<0.05. Mean and standard 
deviation (SD) are shown in the results,
Ethical considerations
The hospital Human Research Ethics Committee deemed 
the study to be a quality improvement process added to usual 
practice. The clinic nurses invited people to participate and 
contained their verbal consent before they tested Hb and 
microalbumin.
Results
Clinic nurse interviews
Three main themes emerged from the clinic nurse interview 
data: it takes time; we can do it, and training is essential at the 
beginning.
It takes time
All three nurses indicated they had no difficulty operating the 
analysers after training but the additional tests took extra time 
during the already busy clinic screening time, which the nurses 
felt would make routine Hb screening difficult to sustain in the 
long term, unless extra resources were available. One nurse said:
We can do the tests, no worries, but it takes time and the doctors will be 
asking why the patients are not ready. If we have to keep doing it [Hb 
and microalbumin testing] we need more staff.
Another nurse explained that testing Hb was not such a problem 
because the nurses routinely pricked the patient’s finger to 
obtain a drop of blood to test glucose, but described testing 
microalbumin as a “nuisance”.
It’s more a problem with the microalbumin because you have to explain 
how to collect the urine, [to the patient] then they go to the toilet and 
come back and that takes time because they are not used to it [urine 
testing].
Having to explain the extra tests to patients who were not 
proficient in English also took time, and compromised 
interpreter time; for example:
A lot of them [patients] can’t speak English so it is difficult making 
them understand the new test. So you have to call the interpreter and 
they are busy too.
Despite these limitations, the nurses felt they were able to 
accurately undertake the tests.
We can do it
The three nurses were very confident in their ability to 
accurately perform Hb and microalbumin tests after the initial 
training. All three indicated they could continue to undertake 
the tests in addition to the usual tests, if resources were available, 
for example:
We can do it, [perform the tests] and we are accurate, but we need 
more resources, more time, more staff if we have to do it all the time.
Training is essential in the beginning
The three nurses indicated that training was essential to their 
ability to accurately perform the tests. As indicated, two of the 
three nurses felt microalbumin testing was more difficult than 
Hb testing until you “get the hang of it”, for example:
It looks pretty easy really and the Hb is I suppose, but the microalbumin 
is not so easy. It took me a while, more goes than the Hb, to get the 
hang of it and get six tests in a row correct.
Patient data
Six hundred and eighty people attended the clinic during the 
study period, all had T2DM: 544 were (80%) were screened. 
Of the 544 people screened, 230 were females; average blood 
glucose 10 (3.9 SD) mmol/L, Hb 127.2 (16.3 SD) g/L, 
microalbumin 47.8 (58 SD) mg/L: 324 were males average 
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blood glucose 10.2 (3.9 SD) mmol/L, Hb 138.6 (18.8 SD) g/L 
and microalbumin 67.9 (3.9 SD) mg/L. The mean age was 62 
years (11.1 SD). Mean duration of diabetes 13.4 years, range 
new diagnosis to 30 years.
All participants had at least one diabetes-related complication: 
most had more than three. Medicines included oral 
hypoglycaemic agents, insulin and a combination of oral 
hypoglycaemic agents and insulin as well as lipid lowering and 
antihypertensive agents. The total proportion of the sample that 
was anaemic was 0.27: 95% CI (range 0.23 to 0.30).
Overall, 25% were anaemic: 22% of females and 27% of 
males. Of these, 29% of females and 27% of males had 
microalbuminuria. There was no significant association 
between age, duration of diabetes, treatment mode and Hb or 
microalbuminuria (p>0.05). The total proportion of the sample 
with microalbuminuria was 0.29: 95% CI (range 0.25 to 0.32).
Discussion
This large prospective study indicates that POCT testing for 
anaemia and microalbumin is feasible in outpatient clinic 
settings. Our study shows outpatient clinic nursing staff can 
be trained to accurately operate the analysers and perform 
Hb and microalbumin tests in addition to their usual clinic 
role. However, the extra tests, especially microalbumin, were 
time-consuming to perform and extra time and resources may 
be needed to achieve optimal screening in OPC settings. For 
example, 136 people attending the OPC during the study 
period were not screened, mostly because of time constraints. 
Alternatively, existing clinic routines could be reorganised. For 
example, blood pressure could be measured by the doctors 
during the consultation, rather than the clinic nurses. Likewise, 
time-related problems may not be such an issue in clinics that 
do not have a high proportion of non-English speaking patients.
POCT testing for a number of clinical indicators has increased 
rapidly in the past decade and is now routinely undertaken 
in health services and by patients at home as part of diabetes 
self-management, for example blood glucose. Unreliable POCT 
results that could put patients at risk have been reported and 
are largely due to inadequate quality testing and equipment 
maintenance (Jahn & Van Aken, 2003). The HemoCue Hb 
meter used in our study is reliable compared with direct 
cyanmethaemoglobin in venous blood, allowing for the slightly 
lower red cell volume in capillary blood (1–3% lower) (Sari et 
al., 2001).
Other researchers confirm Hb measured using the HemoCue 
analyser provides an adequate estimation of the prevalence 
of anaemia, providing the population and site conditions are 
considered (Neufield et al., 2002). Analyser reliability and 
specificity testing were outside the scope of the current study. 
However, routine quality control testing was performed on the 
analysers by the laboratory staff during the study in line with 
quality management practices in the hospital, for example blood 
glucose meter maintenance procedures. In addition, training 
the nurses to perform the tests accurately before the study 
commenced was important to achieve reliable results. A further 
study to confirm the accuracy of the clinic nurses’ testing 
technique by comparing POCT values with laboratory values is 
required.
Twenty-seven per cent of females and 22% of males in our clinic 
were anaemic, which is consistent with rates reported by Li 
Vecchi et al. (2007) and Al-Khoury et al. (2006). However, it is 
higher than 16% Mostafa et al. (2009) reported. None of these 
studies used POCT. The differences in anaemia rates could be 
due to unknown differences in the sampling populations and/or 
differences between laboratory and POCT values.
Anaemia screening is not usually undertaken as part of 
established diabetes complication screening procedures in the 
clinic, even when the patient has declining kidney function, 
POCT Hb and microalbumin testing does not occur in most 
other Australian diabetes OPCs. However, diabetes complication 
screening and management guidelines, including those for 
diabetic renal disease, do not include screening for anaemia, 
which could influence clinical practice. For example, Hb 
is not mentioned in Diabetes Management in General Practice 
(RACGP and Diabetes Australia 2011–12), which most 
Australian general practitioners refer to. Likewise, the Joslin 
Diabetes Centre Screening and Treatment Recommendations for 
Micro- and Macroproteinuria (Korenman & Khan, 1999) does not 
recommend Hb screening. Laboratory albumin, but not POCT 
albumin testing is recommended in these guidelines.
Mild anaemia, like microalbuminuria and retinopathy, is usually 
symptomless. Proactively screening to detect microvascular 
disease is standard practice. It could also be useful to routinely 
screen for anaemia to enable haematological investigations such 
as iron, vitamin B12, folate, and most importantly, infection to 
aid treatment decisions at the point of care. Our study suggests 
Hb and microalbumin POCT testing is feasible if staff members 
are trained and adequate time is available. This is an important 
finding, given the Australian Government focus on managing 
T2DM in primary care and the important role practice nurses 
play in educating people to self-manage their diabetes, including 
complication screening.
The growing knowledge about the biological basis of diabetes 
and its complications and the increasing range of new 
medications and technology represents increasing opportunities 
for implementing risk reduction strategies, prevention and 
early treatment. Screening, preventing and communicating 
risks to relevant individuals are essential elements of risk 
reduction (Kuriyama et al., 1997). Research into diabetes risk 
communication is limited: what research there is suggests 
many people are not aware of their individual risks or how to 
reduce them, and this may be particularly relevant to the risk of 
anaemia.
However, while screening for anaemia is desirable, management 
once anaemia is detected is less clear. Various clinical measures 
are used to prevent or slow the progression of diabetic CKD 
and may also slow or prevent the development of renal anaemia, 
Until recently erythrocyte stimulating agents (EPO) were 
advocated to treat CKD-related anaemia; however, recent 
research suggests higher Hb targets and the erythropoietic (ESA) 
regimens used to achieve the targets may be harmful (Trial to 
Reduce Cardiovascular Events with Aranesp Therapy (TREAT) 
Pfeffer et al., 2009). TREAT demonstrated small improvements 
in energy and quality of life but there was an increased risk of 
stroke in DM with CKD and Hb target 12.5 gm/L.
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Publication of the TREAT findings sparked a debate about the 
risks and benefits of current CKD-related anaemia management 
guideline recommendations. Subsequently, the US Food 
and Drug Administration (FDA) convened a public advisory 
committee in 2010 to examine the use of EPO in managing 
anaemia associated with CKD. Likewise, various experts 
recommended undertaking randomised controlled trials to 
determine optimal Hb targets and management regimens for 
managing anaemia in CKD (Goldsmith & Covic, 2010; Unger 
et al., 2010). Once completed, current guideline developers such 
as the National Kidney Foundation Disease Outcomes Quality 
Initiative (KDOQI) and Kidney Disease: Improving Global 
Outcomes (KDIGO) and diabetes organisations might need to 
review their recommendations. Our study, combined with other 
research, suggests diabetes guideline developers might need to 
consider including Hb testing in existing diabetes complication 
screening guidelines when they are reviewed.
Managing anaemia associated with diabetes-related CKD is 
complicated. Determining the cause of mild asymptomatic 
anaemia and proceeding to identify reversible factors may 
be cost-effective and improve outcomes, if instituted early. 
Nutritional review and regular Hb monitoring may be useful to 
differentiate lethargy from other causes such as hyperglycaemia 
and detect and treat anaemia early. Contributing or confounding 
factors such as excess alcohol intake, which reduces folate and 
vitamin B12 levels and exacerbates existing anaemia, chronic 
blood loss and gastrointestinal disease, which can affect the 
absorption of essential nutrients, and medication review to 
determine whether medicines such as aspirin and non-steroidal 
anti-inflammatory agents and metformin could be underlying 
contributory factors, need to be considered. We did not assess 
these factors in our study but they could easily be incorporated 
into a risk screening tool that could be completed when the 
POCT Hb test is performed. However, such a tool would need 
to be validated.
Implications of the findings
•	  Routine anaemia screening in diabetes outpatient clinics is 
feasible and nurses can be educated to accurately perform 
POCT Hb and microalbumin tests, but testing is time-
consuming and adds to the workload, especially if patients 
are not proficient in English.
•	  Training staff to ensure they are competent to use the 
analysers, is important.
•	  People with diabetes attending routine diabetic outpatient 
clinics have high rates of anaemia. Rates are likely to be 
similar in general practice settings, thus, POCT Hb testing 
could be considered in general practice settings.
•	  Research to determine the cost benefit of including POCT 
Hb testing in current diabetes management guidelines 
would be useful, but was not part of our study.
Strengths and limitations of the study
The strength of the study lies in the large sample size and the 
fact it was undertaken in a “real life” clinical setting with a 
heterogeneous group of participants. The limitations include 
the lack of a control group; however, the study was designed 
to test the feasibility and usability of POCT in routine clinical 
practice. It is not clear whether the 136 PWD who were not 
screened were different from the 544 who were screened but 
the demographic data obtained in the study is similar to random 
samples undertaken in the same OPC in other studies, thus 
they are unlikely to be significantly different. There could be 
other explanations for the anaemia besides CKD. The possible 
reporting bias and lack of a validation of the nurses’ POCT tests 
with laboratory values are also limitations of the study.
The microalbumin mean and SD data we presented suggests 
there was a wide range of values and the median and IQ range 
should have been used.
Conclusions
Clinic nurses can be trained to competently undertake POCT 
anaemia and microalbumin screening but such screening is 
time-consuming and adds to the nurses’ workload. There was 
a significant prevalence of anaemia in our clinic population 
and a significant percentage of people with anaemia had 
microalbuminuria. The high prevalence of anaemia is consistent 
with several previous studies and suggests there could be a need 
for routine Hb testing in people with diabetes, especially those 
CKD.
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Is point of care testing for anaemia (Hb) and microalbumin feasible in people with type 2 
diabetes attending diabetes outpatient clinics?
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